Frontier Biotech, invested by New Value Capital, was listed on the Science and Technology Innovation Board on October 2020, 10 under the stock code: 28. With an offering price of RMB688221.20, Frontier Biotech issued a total of 50.8996 million RMB ordinary shares, raising a net amount of RMB17.17 billion.

 

 

Founded in 2013, Frontier Biotech is an innovative biopharmaceutical company based in China, facing the world and internationally competitive, committed to the research, development, production and sales of innovative drugs for major unmet clinical needs. At present, Frontier Biotech has one new drug on the market, and two new drugs under development are in the clinical trial stage. According to the prospectus, the company's development of aconine is the world's first long-acting human immunodeficiency virus (HIV) fusion inhibitor. Ekonin is a national first-class new drug, China's first original innovative drug for the treatment of AIDS, and the world's first long-acting HIV fusion inhibitor. At the same time, Akonin broke the monopoly of foreign pharmaceutical companies on new anti-AIDS drugs and established China's innovation capabilities in this field. The listing and broad market prospects of Ekonin provide a solid foundation for the company to further enhance its core competitiveness and new drug research and development strength.

 

Different from the AIDS drugs that have been marketed in China, Ekonin has four significant characteristics and advantages: first, it has a unique mechanism of action and is effective against the main epidemic HIV-1 virus, including drug-resistant viruses; The second is injection administration, which has a faster onset of action than oral drugs, meets the medication needs of patients who are intolerant to oral drugs, and is especially suitable for severe patients; Third, it only needs to be administered once a week, which is long-acting and the efficacy is comparable or better than the therapy recommended by the World Health Organization, which reduces the drug burden and side effects caused by daily medication to patients and improves patients' medication compliance; Fourth, it has a unique metabolic pathway, high safety, few side effects, and small interaction with other drugs.

 

 

Congratulations to Frontier Biotech for its successful IPO landing on the Science and Technology Innovation Board and entering a new stage of development. It is hoped that with the help of the capital market in the future, Frontier Biotech can create greater value for patients!